Backed by Novo, Johnson & Johnson, Novartis and Pfizer, the immuno-oncology drug developer was previously reported in April 2015 to be seeking a $105m offering.

The Roche-backed oncology treatment developer floated below its range in an IPO in which Pfizer and Bristol-Myers Squibb both acquired shares.

The Samsung-backed flash storage technology provider will float at the middle of the IPO's range, and could potentially raise up to $489m.

The Pfizer, Baxter and Celgene-backed oncology company will raise $43.7m from an initial public offering where the share price was effectively halved in the space of two weeks.

The flash storage company, backed by Samsung, has set the range for its initial public offering at $16 to $18 per share, expecting to raise up to $450m.

ProSiebenSat.1 and Access Industries-backed music streaming service Deezer is set to float on the Paris stock exchange by the end of the year.

Novartis-backed Nabriva has floated on Nasdaq, raising the amount of proceeds it expected when it filed in June 2015.

GlaxoSmithKline-backed RegenXBio filed for its initial public offering last month when it expected to raise up to $100m.

Road builder Sadbhav Infrastructure Projects secured $31.6m from anchor investors including Tata and Tata AIG Life Insurance as part of the initial public offering.

The cancer treatment developer has raised $94m in equity and grant funding, with Pfizer, Celgene and Baxter among its shareholders.